Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Skin Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Depression 1

Interventions

Vincristine 3Methotrexate 3Mercaptopurine 3Etoposide 3Daunorubicin 3Cytarabine 3Cyclophosphamide 3Asparaginase 3Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Dexamethasone 2pegaspargase 1fludarabine 1etoposide phosphate 1blinatumomab 1aldesleukin 1Rituximab 1Prednisone 1Pirinitramide 1Morphine 1Interleukin-2 1Idarubicin 1Histamine 1Cladribine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasm, Residual × Interleukin-2 × Clear all
NCT01347996 2017-11-29

Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia

Cytovia, Inc.

Phase 4 Completed
84 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡